EML4 and lung carcinoma: Among other commonly detected mutations in lung cancer patients, KRAS mutations were identified in approximately 4.5 % of cases, while EML4-ALK fusions were detected in only 0.5 % of patients, suggesting potential limitations of ctDNA profiling in detecting fusions.